Cingulate Inc. — 2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. The filing was signed March 28, 2022. This is an annual report, not a standalone fourth-quarter report; quarterly financial results are not provided in the supplied filing text.
Business context
Cingulate is a clinical-stage biopharmaceutical company with no approved products or operating revenue. It is developing a proprietary Precision Timed Release (PTR) tablet platform, initially for ADHD, and describes CTx-2103 as an early-stage anxiety program. Its lead candidate, CTx-1301 (dexmethylphenidate), had completed a Phase 1/2 bioavailability study; CTx-1302 (dextroamphetamine) remained in development. The company completed its IPO in December 2021 and began Nasdaq trading that month.
Financial results and liquidity
| Metric | 2021 | 2020 | Change / context |
|---|---|---|---|
| Revenue | $0 | $0 | No revenue since inception |
| Research and development expense | $8.41 million | $5.09 million | Up 65.1% |
| General and administrative expense | $12.27 million | $1.99 million | Up 516.2% |
| Operating loss | $20.68 million | $7.08 million | Loss increased |
| Net loss | $20.71 million | $7.18 million | Loss increased 188.3% |
| Net loss per share | $(2.79) | Not presented | 2021 weighted-average shares: 7,413,579 |
| Net cash used in operating activities | $10.43 million | $6.81 million | Cash use increased $3.62 million |
| Cash and cash equivalents at year-end | $16.49 million | $1.20 million | Funded principally by IPO and private capital |
Margins: Not meaningful because the company had no revenue. The 2021 loss included a $12.74 million noncash charge from converting profits-interest units in the reorganization merger: approximately $8.2 million in G&A and $4.5 million in R&D. The filing also reports $0.71 million of depreciation.
Financing and balance sheet: The IPO generated $25.0 million gross and approximately $20.4 million net proceeds after underwriting discounts and offering costs. The company repaid approximately $0.5 million of related-party notes in December 2021; notes payable were zero at year-end. Total liabilities were $2.04 million, including lease obligations; total assets were $22.89 million. Operating and finance lease liabilities totaled approximately $1.18 million.
Cash-flow context: Investing activities used $0.81 million, primarily for property and equipment; financing activities provided $26.54 million. The filing says the remaining approximately $329,000 of equipment installments was paid in March 2022.
Material changes versus 2020
- Net loss rose to $20.71 million from $7.18 million. Expense growth reflected the one-time profits-interest modification charge, increased personnel costs, and expenses of operating as a public company.
- R&D expense increased despite lower clinical-operations spending: CTx-1301 activity in 2021 was primarily Phase 3 study start-up, while 2020 included costs to complete its Phase 1/2 study.
- The IPO and reorganization materially changed the capital structure. At December 31, 2021, 11,309,412 common shares were outstanding and approximately 5.0 million warrants were outstanding.
- Related-party notes were fully repaid, and deferred employee payroll was paid in December 2021.
Outlook, commentary, and key risks
- Management estimated that year-end cash would fund operations through late 2022 and said approximately $15 million of additional capital would be needed to reach the planned CTx-1301 NDA filing in the second half of 2023. The company was evaluating equity, debt, and strategic collaboration options; no committed external funding source was disclosed.
- The independent auditor’s report and management’s disclosure identify substantial doubt about the company’s ability to continue as a going concern, absent additional financing. The financial statements were prepared on a going-concern basis without adjustments for that uncertainty.
- As of the filing, management planned two CTx-1301 Phase 3 studies in 2022, with fixed-dose study results expected in late 2022 and an NDA submission targeted for the second half of 2023, conditional on positive results. CTx-1302’s planned Phase 1/2 study was targeted for 2023, followed by Phase 3 trials if successful. A CTx-2103 clinical trial was planned for the first half of 2022.
- These timelines and the proposed 505(b)(2) regulatory pathway are plans, not assured outcomes. Clinical efficacy and safety, FDA acceptance of the pathway and evidence, trial enrollment, and approval remain uncertain.
- CTx-1301 and CTx-1302 contain Schedule II controlled substances. DEA quotas, security and distribution rules, and possible diversion concerns could affect supply, trials, or commercialization. The company also relies on third parties for drug substance, manufacturing, and clinical work and had no commercial supply agreement in place.
- Other material risks include continuing losses and financing needs, COVID-19 or other disruptions to trials and supply chains, competition and generic products, reimbursement and pricing pressure, intellectual-property challenges, and the need to establish sales and marketing capabilities or find partners. Management said COVID-19 had not materially affected 2021 results but could affect future operations.
- The company reported no material pending legal proceedings. It reported effective disclosure controls as of year-end; management’s internal-control assessment and auditor attestation were not included because of the transition period for newly public companies.
Important facts for investors to verify
- Current cash, subsequent financing, and actual cash runway versus management’s late-2022 estimate and approximately $15 million funding need.
- Whether the planned CTx-1301 trials began on schedule, enrolled adequately, and produced results supporting the proposed NDA timetable and 505(b)(2) pathway.
- Progress and results for CTx-1302 and CTx-2103, including whether their stated study plans changed.
- Any changes to manufacturing arrangements, API sourcing, DEA quotas, or commercial supply readiness.
- Warrant terms, potential dilution, and changes in shares outstanding; the filing reports 4,791,665 public-offering warrants at a $6.00 exercise price and 208,333 underwriter warrants at $7.50.